Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.03 USD | -0.66% | -0.66% | -28.03% |
Jan. 05 | CureVac Reports Positive Phase 2 Results for mRNA Covid Vaccines Developed With GSK | MT |
Jan. 05 | GSK, CureVac Plan Late-stage Study of COVID-19 mRNA Vaccine Candidates | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.03% | 683M | |
+9.30% | 45.97B | |
+52.73% | 43.93B | |
+7.15% | 42.34B | |
-8.78% | 28.27B | |
+18.68% | 27.18B | |
-21.92% | 19.44B | |
+14.62% | 13.83B | |
+31.85% | 12.4B | |
+4.47% | 11.45B |
- Stock
- Equities
- Stock CureVac N.V. - Nasdaq
- News CureVac N.V.
- Transcript : CureVac N.V. - Shareholder/Analyst Call